Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Escalating Dose-ranging Study to Evaluate the Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults ≥65 Years of Age

NCT00966238 is registered in ClinicalTrials.gov with VaxInnate Corporation as lead sponsor.

NCT NCT00966238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00966238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Escalating Dose-ranging Study to Evaluate the Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults ≥65 Years of Age
Lead sponsor
VaxInnate Corporation
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
March 31, 2011
Enrollment
120 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

influenza